By systematic analysis of SNPs covering the entire genome, the Center for Genomic Medicine is investigating genes susceptible to various diseases, including atopic dermatitis, bronchial asthma, myocardial infarction, rheumatoid arthritis, osteoarthritis, diabetic nephropathy, obesity, and Crohn's disease as well as genes related to responses to interferon treatment of hepatitis C infection. To date, we have identified genes involved in the onset of myocardial infarction, rheumatoid arthritis, osteoarthritis, disc herniation, bronchial asthma and diabetic nephropathy.
The results of this research will be applied in the "personalized medicine", where an appropriate medication with the minimum risk of adverse reactions is provided to an individual patient. It is well known that the efficacies and adverse reactions to drugs differ widely in different ethnic groups. Research is underway to identify the genes related in the drug response in the Japanese population. This will allow the prescription of an appropriate amount of a right drug to a right patient, as physicians will be able to examine the patient's genes, predict the efficacy and the risk of side effect of the drug in a particular patient. At the SNPResearchCenter, research is underway to identify genes related to the response to interferon and other drugs used for treatment of hepatitis C infection.
Furthermore, if we can isolate genes causative to various diseases whose etiology is unknown or little known, such information will be applied to the development of novel molecular-targeting drugs. Moreover, we hope to develop preventive techniques suitable for individuals, through a prior detection of a higher risk to certain diseases.
The results of our research should contribute to the development of novel medical procedures to provide the better quality of lives.
Our goal is to provide useful genetic information for more appropriate drug treatment (maximum efficacy and minimum adverse reactions) to an individual patient through prediction of the efficacy and the risk of adverse reactions.
Ultimately, we want to apply our research to the discovery of novel molecular-targeting drugs on the basis of the information of disease-causative genes.
Our research is aimed at developing methods to predict individual risks to certain diseases and provide the improvement of quality of life by prevention of diseases.